AI assistant
Sending…
XTL Biopharmaceuticals Ltd. — Share Issue/Capital Change 2017
Jan 25, 2017
7116_rns_2017-01-25_c0c529e8-c71c-4631-b018-04cbe39ba6bd.htm
Share Issue/Capital Change
Open in viewerOpens in your device viewer
_________ false
| ��� �� �� ������������� ��"� | 2 380 |
| X T L BIOPHARMACEUTICALS LTD | |
| Corporation no: 520039470 | 4313 |
| - - - | |
| Israel Securities Authority | Tel Aviv Stock Exchange | C002 ( Public ) | Reported via MAGNA: | 25/01/2017 | ||||||
| www.isa.gov.il | www.tase.co.il | Reference: | 2017-02-009900 | Time of broadcast: 15:42 15:37:39 |
Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
| The corporation is a foreign private issuer as defined by U.S. Securities Laws. |
| Attached hereto is a report on change in the ratio of ADR's from one (1) Depositary Share (�DS�) representing twenty (20) ordinary shares to a new ratio of one (1) DS representing one hundred (100) ordinary shares. |
| XTL_6_K_250117_isa.pdf |
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): | |
| - - - | |
| Stock Exchange/Market: NASDAQ CM | Date of revision of form structure: 29/12/2016 |
| Address: HaCharoshet st 5 , Ra'anana 43656 Israel , Tel: 09-9557080 , Fax: 09-9519708 | |
| E-mail address: [email protected] Company site: www.xtlbio.com | |
| Previous names of reporting entity: XENOGRAFT TECHNOLOGIES LTD | |
| Name of the Signatory: Kntor Ronen Position of Signatory in the reporting corporation: Attorney/Legal Counsel Name of Employer Company: | |
| Address: abba hillel 12 , ramat gan 5250606 Telephone: 03-6133371 Facsimile: 03-6133372 E-mail: [email protected] 1 | |
More from XTL Biopharmaceuticals Ltd.
Report Publication Announcement
2026
May 24
Delisting Announcement
2026
May 24
Regulatory Filings
2026
May 22
Proxy Solicitation & Information Statement
2026
May 16
Proxy Solicitation & Information Statement
2026
May 16
Proxy Solicitation & Information Statement
2026
May 15
Regulatory Filings
2026
May 7
Regulatory Filings
2026
May 7
Regulatory Filings
2026
May 7
Regulatory Filings
2026
May 1